These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Triamcinolone acetonide in silicone-filled eyes as adjunctive treatment for proliferative vitreoretinopathy: a randomized clinical trial. Ahmadieh H; Feghhi M; Tabatabaei H; Shoeibi N; Ramezani A; Mohebbi MR Ophthalmology; 2008 Nov; 115(11):1938-43. PubMed ID: 18584876 [TBL] [Abstract][Full Text] [Related]
7. Intravitreal daunomycin induces multidrug resistance in proliferative vitreoretinopathy. Esser P; Tervooren D; Heimann K; Kociok N; Bartz-Schmidt KU; Walter P; Weller M Invest Ophthalmol Vis Sci; 1998 Jan; 39(1):164-70. PubMed ID: 9430558 [TBL] [Abstract][Full Text] [Related]
8. [Antiproliferative effect of sustained drug delivery system of all-trans retinoic acid implant into rabbit's vitreous cavity for treatment of proliferative vitreoretinopathy]. Yan XR; Dong XG; Chen N; Wang W Zhonghua Yan Ke Za Zhi; 2003 Oct; 39(10):621-5. PubMed ID: 14766078 [TBL] [Abstract][Full Text] [Related]
9. Ribozyme to proliferating cell nuclear antigen to treat proliferative vitreoretinopathy. Mandava N; Blackburn P; Paul DB; Wilson MW; Read SB; Alspaugh E; Tritz R; Barber JR; Robbins JM; Kruse CA Invest Ophthalmol Vis Sci; 2002 Oct; 43(10):3338-48. PubMed ID: 12356843 [TBL] [Abstract][Full Text] [Related]
10. [Efficacy of 5-fluorouracil polyactic acid microsphere in prevention of proliferative vitreoretinopathy]. Bi HS; Cui Y; Zhang JH; Wang XR; Xie XF Zhonghua Yan Ke Za Zhi; 2006 Jan; 42(1):37-41. PubMed ID: 16638279 [TBL] [Abstract][Full Text] [Related]
11. Randomized controlled trial of combined 5-Fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy. Wickham L; Bunce C; Wong D; McGurn D; Charteris DG Ophthalmology; 2007 Apr; 114(4):698-704. PubMed ID: 17398320 [TBL] [Abstract][Full Text] [Related]
12. Effect of oral 13-cis-retinoic acid treatment on postoperative clinical outcome of eyes with proliferative vitreoretinopathy. Chang YC; Hu DN; Wu WC Am J Ophthalmol; 2008 Sep; 146(3):440-446. PubMed ID: 18599016 [TBL] [Abstract][Full Text] [Related]
13. Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study. Kon CH; Occleston NL; Aylward GW; Khaw PT Invest Ophthalmol Vis Sci; 1999 Mar; 40(3):705-12. PubMed ID: 10067974 [TBL] [Abstract][Full Text] [Related]
14. [Effect of genistin on proliferative vitreoretinopathy]. You J; Jiang D Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Jul; 35(7):749-53. PubMed ID: 20693719 [TBL] [Abstract][Full Text] [Related]
15. [Clinical risk factors for postoperative proliferative vitreoretinopathy (PVR). A prospective study]. Rodríguez de la Rúa E; Martínez V; Aragón J; Sanabria RM; Giraldo A; Mayo A; Pastor JC; Miranda I; García Arumí J Arch Soc Esp Oftalmol; 2003 Feb; 78(2):91-7. PubMed ID: 12647249 [TBL] [Abstract][Full Text] [Related]
16. New drugs with novel therapeutic characteristics. Have they been subject to randomized controlled trials? Lexchin J Can Fam Physician; 2002 Sep; 48():1487-92. PubMed ID: 12371307 [TBL] [Abstract][Full Text] [Related]
17. Sustained release of cis-hydroxyproline in the treatment of experimental proliferative vitreoretinopathy in rabbits. Yasukawa T; Kimura H; Tabata Y; Miyamoto H; Honda Y; Ogura Y Graefes Arch Clin Exp Ophthalmol; 2002 Aug; 240(8):672-8. PubMed ID: 12192462 [TBL] [Abstract][Full Text] [Related]
18. A new model of proliferative vitreoretinopathy. Frenzel EM; Neely KA; Walsh AW; Cameron JD; Gregerson DS Invest Ophthalmol Vis Sci; 1998 Oct; 39(11):2157-64. PubMed ID: 9761295 [TBL] [Abstract][Full Text] [Related]
19. Proliferative vitreoretinopathy: does oral low-dose colchicine have an inhibitory effect? A controlled study in humans. Berman DH; Gombos GM Ophthalmic Surg; 1989 Apr; 20(4):268-72. PubMed ID: 2733993 [TBL] [Abstract][Full Text] [Related]
20. A prospective study of matrix metalloproteinases in proliferative vitreoretinopathy. Kon CH; Occleston NL; Charteris D; Daniels J; Aylward GW; Khaw PT Invest Ophthalmol Vis Sci; 1998 Jul; 39(8):1524-9. PubMed ID: 9660504 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]